A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering. . . . → Read More: Multi-Drug Resistance Antibiotic Developer to Issue IPO
|
|||||
 Comments are closed  Finance  biomedical, biotechnology, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, pharmaceuticals A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering. . . . → Read More: Cancer Gene Therapy Company Raises $85M in IPO Comments are closed Finance biomedical, biotechnology, cancer, clinical trials, equity, investment, IPO, life sciences, pharmaceuticals, university A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million. . . . → Read More: Medical Robotics Company Crowdfunding IPO Comments are closed Finance biomedical, crowdfunding, engineering, equity, investment, IPO, licensing, life sciences, medical device, physical sciences, robotics, university A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering. . . . → Read More: Immunotherapy Biotech Raises $102 Million in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, cancer, clinical trials, entrepreneurs, equity, investment, IPO, licensing, life sciences, pharmaceuticals Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering. . . . → Read More: Biopharm Company Raising $40 Million in IPO Comments are closed Finance biomedical, biotechnology, equity, investment, IPO, life sciences, pharmaceuticals Selecta Biosciences, a biotechnology company developing treatments harnessing the immune system, is raising $70 million in its initial public offering. . . . → Read More: Immunotherapy Company Raises $70 Million in IPO Comments are closed Finance biomedical, biotechnology, equity, investment, IPO, life sciences, nanotechnology, physical sciences Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley) 6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. At . . . → Read More: Genome-Editing Company Raises $108 Million in IPO Comments are closed Finance biomedical, biotechnology, entrepreneurs, genomics, IPO, licensing, life sciences, nanotechnology, pharmaceuticals, stem cells (A. Kotok) 18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced at . . . → Read More: Cancer Diagnostics Company Raises $12.3M in IPO Comments are closed Finance biomarkers, biomedical, cancer, equity, Europe, investment, IPO, life sciences, medical device (bfishadow, WikimediaCommons) 3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, . . . → Read More: Genome-Editing Company Raises $94 Million in IPO Comments are closed Finance biomedical, biotechnology, entrepreneurs, equity, genomics, investment, IPO, licensing, life sciences, pharmaceuticals (bfishadow, WikimediaCommons) 11 November 2015. Voyager Therapeutics, a company less that two years old developing gene therapies for central nervous system disorders is raising $70 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, trading on the Nasdaq exchange (symbol: VYGR), offered 5 million shares yesterday at $14.00. Shares closed today at . . . → Read More: Gene Therapy Company Raises $70 Million in IPO Comments are closed Finance biomedical, biotechnology, entrepreneurs, equity, investment, IPO, licensing, life sciences, pharmaceuticals, university, venture capital |
One Blood Test Fits All Diseases A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
||||
|
Copyright © 2018 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
